Study to Evaluate the Efficacy and Safety of SYSA1901 vs. Perjeta® of HER2-Positive Breast Cancer
Status:
Recruiting
Trial end date:
2026-02-21
Target enrollment:
Participant gender:
Summary
This is a phase Ⅲ, double-blind, randomized, parallel-controlled, multicenter equivalence
study to compare the efficacy and safety of SYSA1901 + trastuzumab + docetaxel vs. Perjeta® +
trastuzumab + docetaxel in the participants with early-stage or locally advanced
HER2-positive and HR-negative breast cancer with a primary tumor > 2 cm.